Abstract 297P
Background
Palliative care services are bieng provided to advanced cancer patients, and have traditionally included symptom directed therapy, counselling regarding goals of care and discussions centered around aggressiveness of care. An early palliative mliaison is bieng offered to patients with recently diagnosed tumours, but the ambit, purview and scope of these services has remained essentially unchanged.
Methods
Details of 127 patients admitted to the ward between over the course of three months were recorded and analysed.
Results
Analgesic titration (54 percent), interventional pain management (15 percent) and provision of supportive care services (23 percent) were the most common indications for admission. 44/123 patients (35.7 percent) received services which can be considered to be within the purview of supportive care. Bisphosphonate infusion for prevention of skeletal related events (12), pigtail catheter insertion for malignant pleural effusion (4), ultrasound guided therapeutic paracentesis (5), octreotide infusion for symptom control in neuroendocrine tumours and malignant bowel obstruction (3), management of difficult to control symptoms including dyspnoea and pain, malignant bowel obstruction (2), chemotherapy related complications (including febrile neutropenia, mucositis and diarrhea) were among services provided upon inpatient admission. 3 patients recieved chemotherapy. 13/127 recieved consultation liasion during their stay in the ward. Medical oncology liaison was the most commonly sought. The most commonly prescribed opioid was morphine followed by fentanyl and tramadol. Average duration of stay was 1.2 days with the longest admission lasting 5 days. The duration of stay was significantly longer for those who also recieved supportive care (p<0.01). Morphine equivalent daily dose, number of medications prescribed and Eastern cooperative oncology group performance status did not have any effect on the duration of stay.
Conclusions
The nature of services provided under the purview of this model, has the potential to ignite a larger debate on the impending and urgent need to redefine the scope of conventional Palliation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rahul D. Arora.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session